SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Camilla Zimmermann, Dora Yuen, Ashley Mischitelle, Mark D. Minden, Joseph M. Brandwein, Aaron Schimmer, Lucia Gagliese, Christopher Lo, Anne Rydall, Gary Rodin, Symptom burden and supportive care in patients with acute leukemia, Leukemia Research, 2013, 37, 7, 731

    CrossRef

  2. 2
    J How, J Sykes, M D Minden, V Gupta, K W L Yee, A D Schimmer, A C Schuh, S Kamel-Reid, J M Brandwein, The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics, Blood Cancer Journal, 2013, 3, 5, e116

    CrossRef

  3. 3
    Gary Rodin, Dora Yuen, Ashley Mischitelle, Mark D Minden, Joseph Brandwein, Aaron Schimmer, Charles Marmar, Lucia Gagliese, Christopher Lo, Anne Rydall, Camilla Zimmermann, Traumatic stress in acute leukemia, Psycho-Oncology, 2013, 22, 2
  4. 4
    J. A. Kennedy, E. G. Atenafu, H. A. Messner, K. J. Craddock, J. M. Brandwein, J. H. Lipton, M. D. Minden, A. D. Schimmer, A. C. Schuh, K. W. Yee, V. Gupta, Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms, Blood, 2013, 121, 14, 2725

    CrossRef

  5. 5
    Lakshmikanth Katragadda, Bing Z Carter, Gautam Borthakur, XIAP antisense therapy with AEG 35156 in acute myeloid leukemia, Expert Opinion on Investigational Drugs, 2013, 22, 5, 663

    CrossRef

  6. 6
    Vikas Gupta, Tony Panzarella, Le Li, Jabeen Khan, Ajay Sharma, Jeffrey H. Lipton, John Kuruvilla, Hans Messner, Shabbir M.H. Alibhai, A Prospective Study Comparing the Outcomes and Health-Related Quality of Life in Adult Patients with Myeloid Malignancies Undergoing Allogeneic Transplantation Using Myeloablative or Reduced-Intensity Conditioning, Biology of Blood and Marrow Transplantation, 2012, 18, 1, 113

    CrossRef

  7. 7
    Dan Ran, Mario Schubert, Isabel Taubert, Volker Eckstein, Frauke Bellos, Anna Jauch, Hui Chen, Thomas Bruckner, Rainer Saffrich, Patrick Wuchter, Anthony D. Ho, Heterogeneity of leukemia stem cell candidates at diagnosis of acute myeloid leukemia and their clinical significance, Experimental Hematology, 2012, 40, 2, 155

    CrossRef

  8. 8
    Jonathan How, Jenna Sykes, Vikas Gupta, Karen W. L. Yee, Aaron D. Schimmer, Andre C. Schuh, Mark D. Minden, Suzanne Kamel-Reid, Joseph M. Brandwein, Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia, Cancer, 2012, 118, 24
  9. 9
    J M Brandwein, D W Hedley, S Chow, A D Schimmer, K W L Yee, A C Schuh, V Gupta, W Xu, S Kamel-Reid, M D Minden, A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response, Leukemia, 2011, 25, 6, 945

    CrossRef

  10. 10
    Dae-Young Kim, Je-Hwan Lee, Sun Jin Sym, Sung-Cheol Yun, Jung-Hee Lee, Sung-Doo Kim, Yunsuk Choi, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Miee Seol, Kyung-Hwa Lee, Yeon-Joo Lee, Kyoo-Hyung Lee, A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy, Annals of Hematology, 2011, 90, 11, 1283

    CrossRef

  11. 11
    Aaron D. Schimmer, Wolfgang Herr, Mathias Hänel, Gautham Borthakur, Arthur Frankel, Heinz-August Horst, Sonja Martin, Jeannine Kassis, Pierre Desjardins, Karen Seiter, Walter Fiedler, Richard Noppeney, Aristoteles Giagounidis, Christine Jacob, Jacques Jolivet, Martin S. Tallman, Steffen Koschmieder, Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study, Clinical Lymphoma Myeloma and Leukemia, 2011, 11, 5, 433

    CrossRef

  12. 12
    M A Khabori, M El-Emary, W Xu, G Guyatt, A Galal, J Kuruvilla, J Lipton, H Messner, V Gupta, Impact of intensity of conditioning therapy in patients aged 40–60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation, Bone Marrow Transplantation, 2011, 46, 4, 516

    CrossRef

  13. 13
    Holbrook E. Kohrt, Samit Patel, Michelle Ho, Terri Owen, Daniel A. Pollyea, Ravindra Majeti, Jason Gotlib, Steve Coutre, Michaela Liedtke, Caroline Berube, Ash A. Alizadeh, Bruno C. Medeiros, Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience, American Journal of Hematology, 2010, 85, 11
  14. 14
    Biljana Culjkovic, Katherine L. Borden, Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer, Journal of Oncology, 2009, 2009, 1

    CrossRef

  15. 15
    Current Awareness in Hematological Oncology, Hematological Oncology, 2008, 26, 3